6645.Tw

The company's capital structure is characterized by a debt-to-equity ratio of 0.78, indicating a moderate level of leverage. The liquidity position is assessed as medium, with a current ratio of 1.23, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. The company's financial snapshot reveals a negative return on equity of -29.84% and a negative return on assets of -14.39%, indicating poor profitability and asset utilization.

The company's profitability is significantly below industry norms, with a net loss of TWD 146,450,000 and an operating loss of TWD 142,438,000. These figures suggest the company is not generating sufficient revenue to cover its operating costs and is not meeting the preferred metrics for profitability in the biotechnology and medical research industry. The company's gross profit of TWD 84,872,000 is also a concern, as it indicates that the cost of goods sold is consuming a large portion of the revenue, leaving little room for covering other expenses.

The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the geographic exposure or revenue concentration. However, the lack of detailed segment data suggests that the company may be heavily reliant on a single market or product line, which could pose a risk to its financial stability.

The company's growth trajectory is uncertain, as the provided data does not include specific outlook figures for the current or next fiscal year. The negative operating and net income figures indicate that the company is not currently experiencing growth and may be facing challenges in expanding its operations or increasing its market share. The company's capital expenditure of TWD 58,342,000 suggests that it is investing in its operations, but the negative free cash flow of TWD 138,237,000 indicates that these investments are not yet generating positive returns.

The company's risk assessment highlights a medium liquidity risk, with a current ratio of 1.23, and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company is operating with a negative cash balance, which could limit its ability to meet short-term obligations. The company's financial position is further complicated by a negative operating cash flow of TWD 57,167,000, which suggests that the company is not generating enough cash from its operations to sustain its activities.

The company has not disclosed any recent events such as filings or transcripts that would provide insight into its current operations or strategic direction. The absence of such information makes it difficult to assess the company's recent performance or any potential changes in its business strategy.